Calliditas Therapeutics Stock Total Debt
| CALT Stock | USD 19.50 0.05 0.26% |
Calliditas Therapeutics fundamentals help investors to digest information that contributes to Calliditas Therapeutics' financial success or failures. It also enables traders to predict the movement of Calliditas Stock. The fundamental analysis module provides a way to measure Calliditas Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Calliditas Therapeutics stock.
Total Debt To Capitalization is likely to drop to 0.53 in 2024. Calliditas | Total Debt |
Calliditas Therapeutics Company Total Debt Analysis
Calliditas Therapeutics' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Calliditas Therapeutics Total Debt | 966.6 M |
Most of Calliditas Therapeutics' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Calliditas Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Calliditas Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Calliditas Therapeutics is extremely important. It helps to project a fair market value of Calliditas Stock properly, considering its historical fundamentals such as Total Debt. Since Calliditas Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Calliditas Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Calliditas Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Calliditas Total Debt Historical Pattern
Today, most investors in Calliditas Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Calliditas Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Calliditas Therapeutics total debt as a starting point in their analysis.
Calliditas Therapeutics Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Calliditas Net Debt
Net Debt |
|
Based on the latest financial disclosure, Calliditas Therapeutics has a Total Debt of 966.6 M. This is 64.87% lower than that of the Biotechnology sector and 197.61% higher than that of the Health Care industry. The total debt for all United States stocks is 81.82% higher than that of the company.
Calliditas Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Calliditas Therapeutics' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Calliditas Therapeutics could also be used in its relative valuation, which is a method of valuing Calliditas Therapeutics by comparing valuation metrics of similar companies.Calliditas Therapeutics is currently under evaluation in total debt category among related companies.
Calliditas Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Calliditas Therapeutics from analyzing Calliditas Therapeutics' financial statements. These drivers represent accounts that assess Calliditas Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Calliditas Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 6.8B | 12.4B | 11.4B | 9.4B | 13.9B | 14.6B | |
| Enterprise Value | 6.0B | 11.4B | 10.6B | 8.9B | 13.9B | 14.6B |
Calliditas Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Calliditas Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Calliditas Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Calliditas Therapeutics' value.| Shares | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 602 | Simplex Trading, Llc | 2023-12-31 | 324 | Bank Of America Corp | 2023-12-31 | 313 | Rhumbline Advisers | 2023-12-31 | 164 | Colonial Asset Management Inc | 2023-12-31 | 105 | Cutler Group Lp | 2023-12-31 | 100.0 | Qube Research & Technologies | 2023-12-31 | 72.0 | Missouri Trust & Investment Co | 2023-12-31 | 35.0 | Nalls Sherbakoff Group, Llc | 2023-09-30 | 35.0 | Bvf Inc | 2023-09-30 | 750 K | Deutsche Bank Ag | 2023-12-31 | 50.5 K |
Calliditas Fundamentals
| Return On Equity | -0.85 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.39) % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 1.04 B | ||||
| Shares Outstanding | 26.84 M | ||||
| Shares Owned By Institutions | 2.86 % | ||||
| Number Of Shares Shorted | 7.11 K | ||||
| Price To Book | 16.34 X | ||||
| Price To Sales | 0.45 X | ||||
| Revenue | 1.21 B | ||||
| Gross Profit | 787.68 M | ||||
| EBITDA | (370.95 M) | ||||
| Net Income | (466.19 M) | ||||
| Total Debt | 966.6 M | ||||
| Debt To Equity | 0.66 % | ||||
| Current Ratio | 5.32 X | ||||
| Cash Flow From Operations | (434.65 M) | ||||
| Short Ratio | 1.31 X | ||||
| Earnings Per Share | (1.61) X | ||||
| Target Price | 41.76 | ||||
| Number Of Employees | 192 | ||||
| Beta | 1.4 | ||||
| Market Capitalization | 521.96 M | ||||
| Total Asset | 1.86 B | ||||
| Retained Earnings | (2.31 B) | ||||
| Working Capital | 868.01 M | ||||
| Net Asset | 1.86 B |
About Calliditas Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Calliditas Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Calliditas Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Calliditas Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Calliditas Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Calliditas Therapeutics' short interest history, or implied volatility extrapolated from Calliditas Therapeutics options trading.
Pair Trading with Calliditas Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Calliditas Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Calliditas Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Calliditas Stock
| 0.66 | ELYM | Eliem Therapeutics Upward Rally | PairCorr |
| 0.55 | ACB | Aurora Cannabis Sell-off Trend | PairCorr |
| 0.42 | MRK | Merck Company Financial Report 6th of August 2024 | PairCorr |
The ability to find closely correlated positions to Calliditas Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Calliditas Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Calliditas Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Calliditas Therapeutics to buy it.
The correlation of Calliditas Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Calliditas Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Calliditas Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Calliditas Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Calliditas Therapeutics Piotroski F Score and Calliditas Therapeutics Altman Z Score analysis. For more information on how to buy Calliditas Stock please use our How to Invest in Calliditas Therapeutics guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Calliditas Stock analysis
When running Calliditas Therapeutics' price analysis, check to measure Calliditas Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Calliditas Therapeutics is operating at the current time. Most of Calliditas Therapeutics' value examination focuses on studying past and present price action to predict the probability of Calliditas Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Calliditas Therapeutics' price. Additionally, you may evaluate how the addition of Calliditas Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |
Is Calliditas Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Calliditas Therapeutics. If investors know Calliditas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Calliditas Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.61) | Revenue Per Share 44.972 | Quarterly Revenue Growth 0.052 | Return On Assets (0.12) | Return On Equity (0.85) |
The market value of Calliditas Therapeutics is measured differently than its book value, which is the value of Calliditas that is recorded on the company's balance sheet. Investors also form their own opinion of Calliditas Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Calliditas Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Calliditas Therapeutics' market value can be influenced by many factors that don't directly affect Calliditas Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Calliditas Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Calliditas Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Calliditas Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.